The liver serves as a primary site of distant metastases in advanced cancers such as colorectal carcinoma, pancreatic adenocarcinoma, melanoma, lung cancer, and breast cancer.[1] Immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand PD-L1 have revolutionized the management of advanced malignancies, significantly improving overall survival outcomes.[2]. This evidence concerns the gene CTLA4 and pancreatic adenocarcinoma.